Baird lowered the firm’s price target on Medtronic (MDT) to $103 from $109 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic upgraded to Buy from Hold at Nephron Research
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Medtronic’s Strategic Advancements and Early FDA Approval of Hugo Boost Buy Rating
- Medtronic’s Strategic Moves and Market Position: Balancing Growth Prospects with Current Valuation
- Medtronic’s Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain Impact